ATMP specialist Cobra Biologics builds Sweden’s first 500 litre bioreactor investing €20 million at its Matfors facility in Sundsvall.
The global market for DNA vaccines, gene and immunotherapy manufacturing is set to accelerate. More and more patients are being treated for gene-related diseases and cancers using the promising approach of inserting or editing genes in cells and tissues.
Cobra Biologics, an experienced CDMO and a biotechnology leader with ATMP production sites in Sweden and the UK, is now building on its 20 years of success. The company has invested €20 million in two new production lines in Matfors, Sweden – installing the country’s first 500 litre bioreactor for plasmid DNA and microbiota production.
Read the full article at Business Sweden.